(meningococcal group ACWY polysaccharide conjugate vaccine adsorbed)
The Nimenrix Summary of Product Characteristics (SmPC) is available here.
Nimenrix is indicated for active immunisation of individuals from the age of 6 weeks against invasive meningococcal disease caused by Neisseria meningitidis groups A, C, W-135, and Y.
Nimenrix should be used in accordance with available official recommendations.
*Contact Medical Information. 09h - 18h Monday to Friday.
Submit a medical question for Pfizer prescription products.
To report an adverse event related to a Pfizer product, click on the link:
www.pfizersafetyreporting.com
If you cannot use the above website, please contact Pfizer pharmacovigilance at
FRA.AEReporting@pfizer.com.
You may also report adverse events online on the Ministry of Health’s website ‘Portail de signalement des événements sanitaires indésirables’ at https://signalement.social-sante.gouv.fr